REG - SkinBioTherapeutics - Notice of IMC Shareholder Presentation

SkinbiotherapeuticsAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250627:nRSa6537Oa&default-theme=true

RNS Number : 6537O  SkinBioTherapeutics PLC  27 June 2025

SkinBioTherapeutics plc
("SkinBioTherapeutics" or the "Group" or the "Company")

Presentation on Superdrug Commercial Agreement

via Investor Meet Company platform

 

27 June 2025 - SkinBioTherapeutics plc (AIM: SBTX), a life science group
focused on skin health, will be providing a short presentation to shareholders
on Thursday 3 July 2025 at 11am BST about the recently signed exclusive UK
commercial agreement with Superdrug Stores plc, one of the UK's leading beauty
and health retailers, related to its AxisBiotix™ food supplements to
alleviate the symptoms of inflammatory skin conditions.

The presentation will be open to all existing and potential
SkinBioTherapeutics shareholders. Investors who already follow
SkinBioTherapeutics on the Investor Meet Company (IMC) platform will be
invited automatically. Investors can sign up to Investor Meet Company for
free Here (https://www.investormeetcompany.com/) .

The Company intends to hold an IMC shareholder presentation at a later date
for a pre-close trading update.

-Ends-

For more information please contact:

 SkinBioTherapeutics plc                                  +44 (0) 191 495 7325

 Stuart J. Ashman, CEO

Simon Hewitson, COO

 Singer Capital Markets (Nominated Adviser & Broker)      +44 (0) 020 7496 3000

 Philip Davies

 Sam Butcher

 Patrick Weaver

 Vigo Consulting (financial press)                        +44 (0) 20 7390 0230

 Rozi Morris                                              SkinBio@vigoconsulting.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Group's proprietary platform technology, SkinBiotix®, is based upon
discoveries made by the translational dermatology team at the University of
Manchester.

The Group's foundation business is targeting the skin healthcare market via
five pillars, the most advanced of which are cosmetic skincare (SkinBiotix)
and food supplements that harness the gut-skin axis (AxisBiotix). The cosmetic
pillar has a partnership with Croda plc and the Group's first in-house
product, AxisBiotix-Ps™, a food supplement to alleviate the symptoms of
inflammatory skin conditions, is sold directly and via Amazon, and will be
sold via an exclusive UK commercial deal with Superdrug Stores plc later in
2025.

The Group is also acting as a consolidator and is making acquisitions in
complementary areas such as skin care and cosmetic applications, that also
bring new distribution and geographical platforms, and manufacturing
capabilities through which it can funnel its in-house pillar products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For
more information, visit: www.skinbiotherapeutics.com
(http://www.skinbiotherapeutics.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCKZGZVLVLGKZM